CeNeRx BioPharma
CeNeRx BioPharma, a drug development company, engages in developing therapeutics to treat diseases related to the nervous system.
Business Model:
Revenue: $17.3M
Employees: 51-200
Rankings
Industries / Tags:
Detailed CeNeRx BioPharma Information
Geographic Data
Address: 270 Cornerstone Dr
City: Cary
State: NC
Zip: 27519
Country: US
Financial Info
Stage:
debt financing
Raised Last:
$5M
Raised Total:$59M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company&s;s product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson&s;s and Alzheimer&s;s diseases. The company was founded in 2005 and is based in Cary, North Carolina.
Contact Phone:
+19192344072
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2010 | Debt Financing | $6M | 6/2009 | Debt Financing | $4M | 6/2012 | Debt Financing | $5.2M | 1/2010 | Debt Financing | $3.5M | 9/2008 | Series B | 3 | $15M |
A. M. Pappas &a; Associates L Capital Partners Perseus-Soros Biopharmaceutical Fund A. M. Pappas &a; Associates L Capital Partners Perseus-Soros Biopharmaceutical Fund |
8/2010 | Series C | $0 |
L Capital Partners Pappas Ventures Perseus L Capital Partners Pappas Ventures Perseus |
2/2012 | Series D | 3 | $4.6M |
Aisling Capital L Capital Partners Pappas Ventures Aisling Capital L Capital Partners Pappas Ventures |
11/2005 | Series A | 2 | $8M |
L Capital Partners Perseus-Soros Biopharmaceutical Fund L Capital Partners Perseus-Soros Biopharmaceutical Fund |
8/2010 | Series C | 3 | $13M |
L Capital Partners Pappas Ventures Perseus L Capital Partners Pappas Ventures Perseus |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
